#Japan #Tokyo #Eisai #Biogen #Leqembi

Groundbreaking New Findings on LEQEMBI Therapy for Early Alzheimer's Patients

Recent data presented at the Alzheimer’s Association International Conference (AAIC) 2025 has illuminated the profound impact of LEQEMBI® (lecanemab-irmb) therapy on early-stage Alzheimer's patients. Conducted by Eisai Co., Ltd. and Biogen Inc., this research highlights that continuous treatment for up to four years not only slows cognitive decline but sustains improvements in patient quality of life.

Study Overview

The study, known as Clarity AD, was a global Phase 3, double-blind, placebo-controlled trial that enrolled 1,795 patients, with the treatment group receiving 10 mg/kg lecanemab bi-weekly. The results are monumental, indicating that after four years of treatment, the average cognitive decline—measured using the Clinical Dementia Rating-Sum of Boxes (CDR-SB)—was reduced by 1.75 points compared to expected outcomes based on the natural progression of Alzheimer’s disease.

Consistent Benefits Observed

Among its significant findings, 56% of patients with low tau levels—indicating less neurodegenerative damage—demonstrated improved cognitive functioning and daily living activities after four years. This is crucial, as early intervention is believed to help patients maintain their independence longer compared to those on placebo.

The CDR-SB scores revealed that within the patient group treated with lecanemab, a beneficial shift was sustained over four years. Previous observations noted a decline rate that was reduced by 1.01 points after three years; however, it grew more pronounced to 1.75 points by the four-year mark, evidencing the treatment's effectiveness over time. These results were stark when contrasted with benchmarks from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, which typically reflects standard progression in Alzheimer's disease.

Safety and Tolerability

Importantly, the trial did not reveal any new safety concerns with extended lecanemab treatment. A consistency noted was a decrease in amyloid-related imaging abnormalities (ARIA) rates after the first year, affirming that ongoing therapy was well-tolerated over four years. Patients' overall health and safety are critical factors in treatment decisions, and these data promote lecanemab as a reliable option for managing early Alzheimer’s.

The Importance of Timing

The significance of initiating treatment in the early stages of Alzheimer's disease is underscored by the study, which showed that 69% of patients who began therapy with low tau levels showed stabilization or improvement in key cognitive assessments. Notably, those employing the ADAS-Cog14 scale also illustrated that 51% of patients demonstrated enhanced scores in cognitive function, which directly correlates with better daily living capabilities over time.

The sustained benefits seen across multiple cognitive scales suggest that maintaining lecanemab treatment is vital for maximizing the patient's potential cognitive longevity.

Collaboration and Future Directions

Eisai is leading the global research and regulatory processes for lecanemab, working closely with Biogen in a solid partnership formed since 2014 focused on developing innovative Alzheimer’s therapies. As lecanemab has gained regulatory approval in 46 countries and awaits further assessments, the companies emphasize ongoing research efforts aimed at enhancing the understanding and treatment of early Alzheimer’s.

In conclusion, these new findings not only highlight the efficacy of LEQEMBI in sustaining cognitive functions over an extended period but also set a precedent for future Alzheimer's treatment protocols, inspiring continued research into effective management strategies for a disease that has long evaded sufficient treatment solutions.